SMAD3 and non-small cell lung carcinoma: TGF-β-pathway activation is a known inducer of EMT and acquired erlotinib resistance in NSCLC,17, 18, 19 but we found no increase in TGF-β1-secretion or activation of SMAD3 in the EMT-subclones (Supplementary Figure S2).